October 4, 2022 GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology August 31, 2022 GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights August 29, 2022 GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31 July 13, 2022 GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood June 23, 2022 GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus June 16, 2022 GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022 June 16, 2022 GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse May 16, 2022 GBS Inc. to Present at the H.C. Wainwright Global Investment Conference May 13, 2022 GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET May 10, 2022 GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
October 4, 2022 GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology
August 31, 2022 GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights
August 29, 2022 GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
July 13, 2022 GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood
June 16, 2022 GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse
May 13, 2022 GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET